Five Prime Therapeutics Inc (FPRX:NASDAQ) Investor Relations Material

Overview

Five Prime Therapeutics is a biotechnology company that aims to develop protein therapeutics for treating cancer and inflammatory diseases. Its leading product candidate, FPA008, is an antibody that blocks colony stimulating factor-1 receptor and is currently in Phase Ib clinical trials for rheumatoid arthritis. The company also has plans to develop FPA008 for pigmented villonodular synovitis and multiple cancers in combination with nivolumab. Overall, Five Prime Therapeutics is focused on advancing its clinical pipeline and improving patient outcomes.

Frequently Asked Questions

What is Five Prime Therapeutics Inc's ticker?

Five Prime Therapeutics Inc's ticker is FPRX

What exchange is Five Prime Therapeutics Inc traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Five Prime Therapeutics Inc's headquarters?

They are based in San Francisco, California

How many employees does Five Prime Therapeutics Inc have?

There are 51-200 employees working at Five Prime Therapeutics Inc

What is Five Prime Therapeutics Inc's website?

It is http://www.fiveprime.com/

What type of sector is Five Prime Therapeutics Inc?

Five Prime Therapeutics Inc is in the Healthcare sector

What type of industry is Five Prime Therapeutics Inc?

Five Prime Therapeutics Inc is in the Biotechnology industry

Who are Five Prime Therapeutics Inc's peers and competitors?

The following five companies are Five Prime Therapeutics Inc's industry peers:

- Agios Pharmaceuticals

- Trillium Therapeutics Inc.

- Biohaven Pharmaceutical Company

- Scholar Rock

- Coherus BioSciences